United Therapeutics (UTHR) Tops Q1 EPS Views; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
EPS Growth %: -10.1%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: -10.1%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $1.32, $0.39 better than the analyst estimate of $0.93. Revenue for the quarter came in at $204.2 million versus the consensus estimate of $203.91 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
- Broadcom Limited (AVGO) PT Lowered to $350 at DA Davidson
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
